

Midori Nakagaki, Emma Munro, Nicole Gavin
Royal Brisbane and Women's Hospital, Brisbane, Australia

Introduction

- MASCC / ISOO publish and maintain evidence-based international guidelines on the management of oral mucositis (OM) → Table
- Adherence to and dissemination of MASCC/ ISOO guidelines have not evaluated.
- EviQ is a web-based cancer treatment protocols and guidelines developed for the Australian context.

Level of evidence	Intervention	Patients
I. Recommendation	PBM	All
I. Recommendation	KGF-1/ palifermin	TBI-based auto
II. Recommendation	Cryotherapy	Melphalan auto
III Expert opinion	Professional oral care	All
III. Suggestion	Multi-agent oral care	All
III. Expert opinion	Education	All
III. Expert opinion	Bland Mouth Rinses	All
II. Recommendation	PCA with morphine	All

PBM: Photobiomodulation, KGF: Keratinocyte Growth Factor, PCA: Patient controlled analgesia, TBI: Total Body Irradiation

Aims



The CAN EAT Survey aimed to evaluate two key aspects related to the management of oral mucositis in hematopoietic stem cell transplant (HSCT) centers across Australia and New Zealand:

1. Assess dissemination of MASCC/ISOO mucositis guidelines.
2. Identify potential barriers to guideline adherence.





Methods

- Specialist nurses in HSCT units of 41 adult hospitals were invited to participate in the survey
 - Survey questions included;
 - General unit information: Number of allogeneic and autologous HSCT per year
 - Guidelines they follow
 - OM assessment: tools, frequency, assessors
 - OM prevention strategies: interventions and enablers/ barriers
 - Treatment strategies: pain management and nutrient supplement
- HREC/2022/RBWH/85181

Results



Results (cont.)



Conclusions

- OM assessment, prevention and treatment vary between institutions even in Australia and New Zealand
- National guidelines are more recognised in mucositis management, compared to the MASCC/ ISOO guidelines
- In Australia and New Zealand, PBM and palifermin are not used nor recognised, potentially due to national guidelines not including them.
- Activities to disseminate the MASCC guidelines and more practical recommendation are required
- Limitations include the survey answered by nurses – medical and dental professions may have different aspects.

References

- Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan R M., Bowen J, Gibson R, Saunders DP, Zadik Y, Ariyawardana A, Correa ME, Ranna V, Bossi P; for the Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020; 126: 4423–4431. <https://doi.org/10.1002/cncr.33100>

- EviQ guidelines <https://www.eviq.org.au/> Accessed 09/05/2024